{"name":"REMD Biotherapeutics, Inc.","slug":"remd-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"REMD-477","genericName":"REMD-477","slug":"remd-477","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"REMD-477","genericName":"REMD-477","slug":"remd-477","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNcnZpNF8tTkEwUUUtbVA1eFpHdEhHVFVWSWh0YnlUa1F5dWxCdWNZcXJJNjFabEwwZk53M1FMOTJZUFNZRXVwd1c2blZqVWZ3UmUxc1ExOWg0M2VXNXBIbHBsOVpGQkdEbzdqYTRWbzF2al9kMXZ0QjlZRDVjMTlRR2Y2M2x1MnBtVXFnSEdLWU1uOGRfdmh2dWlMZDU1QUJLOHpmLUphRFM2RFNMRHV0SlppUWxsUHI4QlZBXzlud1dpbTlUWG5XSFM2QS00S0kyNUVhMmFVZURSbGRURTJlYW1uVkc5Q3JIYmFzd1Q1XzhRb0hxODFZYldVXzVveDVlb0J3R1ZRR1czWENsRTJYZG9MYmhwN1k?oc=5","date":"2026-01-19","type":"pipeline","source":"PR Newswire UK","summary":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNZTFLSG0wTlBQWUR1MllRcVpXMmlIU2lnejhIaDlMSkFINWVpazAtS1Y2cjlrUVlPTXJTel9Yb0RNcGlLS2NmWVp5aTc5OFNfYzZtRjlYRnVDQlc0SlFzWU9KZjBiQ1NzM2NUenNQdHFJeERwWHBJdmIwN0IzVWhNOEZ5MS0zUkRXUTVvVVNaMFhfbEk3aF93aVBiRjMzQXBWX3FYRXhlVWZYeEs5dnBvNXA3cWpZUUtqYWNFblNmZEJPdjdyVEhVX200OFdMc1E5ZjJkLWpWU2l6Q0Nob3N1a0taZ1g3QUpFTUE4STN3QmpwRUlWMTlfTjl0blA?oc=5","date":"2025-08-28","type":"pipeline","source":"prnewswire.com","summary":"GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight - prnewswire.com","headline":"GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOcjBzSXJxdmVIUTA5MXc3VEpSdTRMUGx2MW5FRlppT1VSSndnVFlOUzVwdzFGYTYyQl9rOGxhQTFlM0dhQlhKNDZucVVHbWVZLWxNNkVVVVd0WElkVUNraDhjaUo2ZklYQWRpS1ZCY2dCMXdxSllDMk5BbVFWWmJTYWxIcFdnMXRxUnlSZVNPSzh1YUh5YXpOTXRfMXhJaFNUUjZxcWU2LTd1T25UendtX3BRel9aRHJxLVcxMEgtVU96Yl8wTThxdlU1Yk1zTlk0UzR0Tk1CUjY?oc=5","date":"2025-03-05","type":"pipeline","source":"prnewswire.com","summary":"Global Biosensors Market to Show Positive Growth at a CAGR of ~8% by 2032 | DelveInsight - prnewswire.com","headline":"Global Biosensors Market to Show Positive Growth at a CAGR of ~8% by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNZjVyUVRCNTZDcUxOYlNzd1dRSWZrUE1Qdlh1cEVNY2VHT0c0YU93U1ZuVnpCbzBlMDBkcUxGeHlFbktQbmhaQmpLOGF4bm92cDUxbHpTLUtlbzJ2amVnVy1ieXlsWElUcDRWQ0pYc1Q1N2c1R3hzS1lGcTM4R3dIV1hyTS1Ma0JCRlc5MGduX3V0REYxOVN3QmUwSVFReUVVX3VaUUV3SUJsTGlZTzYtZmFua0NIUnprUmp1V1N0amtUOHNzMTZPbEdQQkhpZ3NnYVI3cENlY25CcXktR3dmaFR0aGIzUExRaE95WmYwRzk1b0kzenNaLWVRMVk5Zw?oc=5","date":"2025-02-27","type":"pipeline","source":"GlobeNewswire","summary":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight - GlobeNewswire","headline":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxONGl0M2pkNFg2SFZMdEFnS0Y1LVRkY3AtNXBpYUtLWkR6WXNOWUl3MlpEeHBZOV9jcUlnWVRscVpDWkJ0OHAxRlFYNGxiRU5mWGNaTS1GWEZJUjJoMG9ZQjlyUVBBYW10WUgzRUJ4eWtVcjk0ZHJzNnlqRGU0VVhzci1sQ0ZYRE16Qjk3N3dCZ1prWVNtUE5XYWROMTBieUxYR3JxUkk1Tlg4N3kzX2Z4LTY5RkhDZUpHX09TTmsyTGlqN0lQN0Iwck1pMXRXS2ctSkJDRE11VExQWm1zcjVTZXlEano4VEpHd1FCRTlrSG5Wbjd1Sk9Ma2k1dGtXQ3kwM1ktejBuc0hOaU5tX2l3TG9ydFhfYXQ4NnN1WGtocGlvcEp6bWZpOEJCc3FfTTVyY3c?oc=5","date":"2024-10-28","type":"trial","source":"prnewswire.com","summary":"Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQTTFOMUVnQnRONkZ3NExua1ppTFk3TE0tZzAtWEl3ZXlKMmNuYzNoQ2ZGRjZVZU9HdE1LQmhWakZmTTFnWm42ajNUNDlvSV9DWVRDdGdxY0ZPRFNQY1dUbHpqQ2trZW95SmNfTk9kMXFGZnJiNEloa0Yzeno0YUttRnk0U3p1QWhnYkpBNG01eDdPVzNqTXd2OXVIcGpCekNVSVdSZXVvczNjelVfbGhSYkF4S2lqel90ME43MkxObVNjSW9md0wxS3ZPaXFMM0dZQmpXZW1WcnBHS1JzakdsYQ?oc=5","date":"2024-09-05","type":"pipeline","source":"prnewswire.com","summary":"Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsight - prnewswire.com","headline":"Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNZXkyTGtGaDllNVk2OURmdDItTVg4Q2U1dTRqVjZ0X1J2UzdIT2pZUlp0ZmtaalJsVS1tUWswMVhvYTZHcTRxZDhjRFV1b2VjU21lMV9iSWxYTkFmTlNKNWJhc0F3SzJ3NGw3cHFnRE8yU3JuSXhjYWp5Ui0xQU13QjlNRFR1VVgyT09xaHRKRVlnbHBTckQtbVlUdjB4eTVnaGczcTRUWmJTd0xDdkl5YlUwcG42azQzbFhZSk9LQkwtSU1sTUNzYjQ0RU5QX2p2Q3hQYjNLY2haVWZjTjkzczNUQjBhTFJpb1h3dGFJaGZVOG1fNzVDUg?oc=5","date":"2024-07-17","type":"pipeline","source":"GlobeNewswire","summary":"Global Peptide Therapeutics Market to Grow Significantly at a CAGR of ~10% by 2030| DelveInsight - GlobeNewswire","headline":"Global Peptide Therapeutics Market to Grow Significantly at a CAGR of ~10% by 2030| DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5qSkxtdkpYUzJyYzRsVmEzT19HU3dkUnZtSTF5a2R1UGtJUlk2MFJDR2lMemNnVEFVM0drdjJRUjhZRDB3bVBwdUVUSkpEeGhaYW16Z1liYkI3dTcweTRFZzlxeEljaXlGdWVHdg?oc=5","date":"2022-11-29","type":"trial","source":"팜뉴스","summary":"A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, received IND clearance from NMPA for clinical trial - 팜뉴스","headline":"A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics, partners of GenScri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQN2ZEWXNWVHZybHlGWUIzMGpoWHBRVGYzLXUwU3BYTkdYNVk4eUVMTHFMLWlBNGh4cVY1Ti1HWUVabGtaUVZKUzliSGhES2NiNEJqUm9BSVNTc29yUTdOdjRPaFdLb24wcDVpNXRXVGhoWGk1RzV3c2YtUVVTNU9FN2JzdGlrb0Q2UWpNbXRSMGlESlMtMEZiRHUzcUJZMWFNWVVXMHB3UFpVTTRyVnhlVE5jMS1fckVOZ2I1Y05mVVZqb2NrS0FwSkFTbUpRZFhfODBmVXV5VmVVc1pSZHBDTm5pUQ?oc=5","date":"2022-06-23","type":"deal","source":"SynBioBeta","summary":"GenScript Biotech & REMD Biotherapeutics Inc. Reached a Strategic Collaboration to Develop Several Bispecific Antibodies - SynBioBeta","headline":"GenScript Biotech & REMD Biotherapeutics Inc. Reached a Strategic Collaboration to Develop Several Bispecific Antibodies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}